Abstract:1. In AML, two SE‐related transcripts IGF2BP2 and IGF2BP3 were identified, whose activation could be triggered by SE machinery. 2. IGF2BP2 and IGF2BP3 strengthened the stability of DDX21 mRNA in an m6 A‐dependent manner. 3. Knockdown of DDX21 inhibited proliferation, promoted apoptosis and led to cell cycle arrest in AML cells. 4. DDX21 recruited transcription factor YBX1 to cooperatively facilitate the transcription of ULK1. Background Acute myeloid leukaemia (AML) is a haematological malignancy with unfavourable prognosis. Despite the effectiveness of chemotherapy and targeted therapy, relapse or drug resistance remains a major threat to AML patients. N6‐methyladenosine (m6A) RNA methylation and super‐enhancers (SEs) are extensively involved in the leukaemogenesis of AML. However, the potential relationship between m6A and SEs in AML has not been elaborated. Methods Chromatin immunoprecipitation (ChIP) sequencing data from Gene Expression Omnibus (GEO) cohort were analysed to search SE‐related genes. The mechanisms of m6 A‐binding proteins IGF2BP2 and IGF2BP3 on DDX21 were explored via methylated RNA immunoprecipitation (MeRIP) assays, RNA immunoprecipitation (RIP) assays and luciferase reporter assays. Then we elucidated the roles of DDX21 in AML through functional assays in vitro and in vivo. Finally, co‐immunoprecipitation (Co‐IP) assays, RNA sequencing and ChIP assays were performed to investigate the downstream mechanisms of DDX21. Results We identified two SE‐associated transcripts IGF2BP2 and IGF2BP3 in AML. High enrichment of H3K27ac, H3K4me1 and BRD4 was observed in IGF2BP2 and IGF2BP3, whose expression were driven by SE machinery. Then IGF2BP2 and IGF2BP3 enhanced the stability of DDX21 mRNA in an m6A‐dependent manner. DDX21 was highly expressed in AML patients, which indicated a poor survival. Functionally, knockdown of DDX21 inhibited cell proliferation, promoted cell apoptosis and led to cell cycle arrest. Mechanistically, DDX21 recruited transcription factor YBX1 to cooperatively trigger ULK1 expression. Moreover, silencing of ULK1 could reverse the promoting effects of DDX21 overexpression in AML cells. Conclusions Dysregulation of SE‐IGF2BP2/IGF2BP3‐DDX21 axis facilitated the progression of AML. Our findings provide new insights into the link between SEs and m6A modification, elucidate the regulatory mechanisms of IGF2BP2 and IGF2BP3 on DDX21, and reveal the underlying roles of DDX21 in AML.

N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

The N6-methyladenosine-mediated Lncrna WEE2-AS1 Promotes Glioblastoma Progression by Stabilizing RPN2

SUMO-specific protease 1 exacerbates acute myeloid leukemia by enhancing beclin 1-dependent autophagy through polypyrimidine tract-binding protein 1 deSUMOylation

Super-Enhancer-Driven IGF2BP2 and IGF2BP3 Promote DDX21 Expression in Acute Myeloid Leukemia

Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia

The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability

m6A‐dependent upregulation of DDX21 by super‐enhancer‐driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia

The N-6-Adenine Methyltransferase Mettl14 Plays an Oncogenic Role in Acute Myeloid Leukemia

m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia

Characterization of m6A regulator‐mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia

The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia

One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia

N6-Methyladenosine on Mrna Facilitates a Phase-Separated Nuclear Body That Suppresses Myeloid Leukemic Differentiation

Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine

Research advances of N6‐methyladenosine in diagnosis and therapy of pancreatic cancer

Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort

Transcriptional regulatory networks mediated by abnormal m6A modifications in tumor development

SENP2 promotes ESCC proliferation through SETDB1 deSUMOylation and enhanced fatty acid metabolism

N6-methyladenosine modification of MALAT1 promotes metastasis via reshaping nuclear speckles

The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma